The production cost of Diethylstilbestrol (DES), a synthetic estrogen previously used in medical and veterinary applications, involves significant capital and operational expenditures. Manufacturing requires investment in complex organic synthesis processes, including condensation reactions, purification, and crystallization to achieve high pharmaceutical-grade purity. The primary cost drivers include raw materials such as phenol derivatives, ethylating agents, catalysts, and solvents, along with specialized reaction and distillation equipment. Additional costs cover utilities, skilled labor, quality control, packaging, transportation, and regulatory compliance with strict pharmaceutical and environmental safety standards, given its known health risks. Market factors such as raw material availability, regulatory restrictions due to its discontinued human medical use, and limited demand in veterinary applications influence overall production costs. Despite these challenges, DES continues to be produced in controlled settings for specific research and industrial purposes.